It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: LightSpeedDriver
a reply to: bobs_uruncle
May we know what that something else is you patented?
originally posted by: LightSpeedDriver
a reply to: Blue Shift
Or maybe the cash-cow that is cancer research is just too lucrative to give up? We're still stuck on chemo and radio therapy after decades of research, which do not work for many forms of cancer. The promise of a longer or better life-quality is often an empty one too. I have witnessed 4 family members die from lung cancer. They rarely last longer than 2 years after "treatment". Caveat emptor.
originally posted by: LightSpeedDriver
a reply to: Blue Shift
I know Phage's story, Non-Hodgkin lymphoma. Not the same as lung cancer which does not respond to chemo/radio.
originally posted by: daskakik
Just going to leave these two links here:
Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent.
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
However, 24 months after the commencement of oral MBZ a scan showed disease progression, and everolimus was added to the MBZ but without additional benefit in disease control.
A screening of 2000 small molecules against melanoma cells lines picked out ten compounds that had inhibitory action against the M-14 and SK-Mel-19 chemoresistant melanoma cells lines, but were non-toxic to normal melanocytes. Of these ten compounds, four were benzimidazoles —mebendazole, albendazole, fenbendazole, and oxybendazole—and of these four compounds, MBZ was selected for more detailed analysis based on its relative lack of toxicity and well-characterised pharmacokinetics.